Keros Therapeutics, Inc. (NASDAQ: KROS) reported Q2 EPS of ($1.27), $0.08 better than the analyst estimate of ($1.35).

For earnings history and earnings-related data on Keros Therapeutics, Inc. (KROS) click here.